Spike S1, Recombinant, SARS-CoV-2, aa13-665, Fc Fusion, Avi-tag (SARS-CoV-2)

Recombinant protein corresponding to aa13-665 from Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), fused at the C-terminus of the Fc portion of human IgG1, and a C-terminal Avi-tag, expressed in a HEK293 cells.||Molecular Weight:|~102kD, runs at a higher MW by SDS-PAGE due to glycosylation.||Assay Conditions:|SARS-CoV-2 S1 and ACE2 binding assay was done using ACE2:SARS-CoV-2 Spike Inhibitor Screening Assay Kit. SARS-CoV-2 S1 protein and anti-human Fc-HRP were used instead of SARS-CoV-2 Spike protein (RBD) and anti-mouse Fc-HRP respectively. Non-specific His-tag protein was coated and used for a negative control.||Applications: |Suitable for use in the study of enzyme kinetics, screening inhibitors and selectivity profiling. Other applications have not been tested. ||Recommended Dilution:|Optimal dilutions to be determined by the researcher.||Storage and Stability:|Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.